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Iron deﬁciency is a common nutrient disorder, affecting nearly 2 billion 
individuals globally, including 30% of women and their offspring. Iron is a 
nutrient with a vital role in proper mitochondrial function. This is 
important in developing neurons; lack of proper amounts of iron can lead 
to impaired memory and learning functions as well as social deﬁcits. 
When supplemented early enough, iron supplements may reverse these 
effects. However, this time frame is very narrow and by the time  iron 
deﬁciency is detectable in newborns, this window has passed. 
Methylene blue is a drug that acts as an alternative electron carrier in the 
electron transport change. This drug improves mitochondrial function and 
enhances memory in some cases. Thus, this would be an ideal option to 
test to reverse the effects of prenatal and early postnatal iron deﬁciency 
in newborns as well as other individuals later in life.  
The hypothesis for this experiment is that treatment with methylene blue 
alone will not yield any signiﬁcant changes from iron deﬁcient neurons 
and treatment with iron and methylene blue together will improve 
dendrite complexity to be similar to control neurons.
n
Chronic Iron Deﬁciency and Treatment of Primary 
Hippocampal Cultures
The DFO treatment group results were in 
line with results from previous experiments. 
In none of the groups was the treatment 
group of MB treated DFO and MB plus iron 
treated DFO neurons statistically similar to 
the control group while being statistically 
signiﬁcant from the DFO and DFOR groups. 
This means the MB treatment did not work 
as expected, and in some cases made the 
groups worse. This is likely due to the 
dosage amount of MB used. In testing done 
since the data collection from this 
experiment, it has been shown that there is 
only a very narrow range in which MB 
treatment will be helpful in aiding 
mitochondrial function and that in some 
cases too much MB can be harmful. This 
experiment would need to be repeated 
with a smaller MB dosage amount in order 
to come to a more accurate conclusion 
about the viability of MB as a treatment 
option for reversing the effects of prenatal 
and early postnatal  iron deﬁciency.  
Figure 1: Average dendritic branch lengths 
within each treatment group (𝛍m).
Figure 2: Average branch length of primary  
dendrite for each neuron  within each 
treatment group (𝛍m).
Figure 3: Average branch length of the 
longest  dendrite for each nuron within each 
treatment group (𝛍m).
Figure 4: Average number of dendritic 
branches for each neuron within each 
treatment group.  Same letter above bar 
represents statistically similar.
Figure 5:  Average 
number of branches 
to reach x distance 
from soma for each 
neuron  within each 
treatment group 
(𝛍m). Colored star 
represents 
matching color 
group is statistically 
different from 
control group.
Figure 6: Average number of primary  
dendrites for each neuron  within each 
treatment group.
Figure 7: Average branch length for all 
dendrites on a single neuron within each 
treatment group. Same letter above bar 
represents statistically similar.
Figure 8: Average length for all dendrites per 
single neuron within each treatment group 
(𝛍m). Same letter above bar represents 
statistically similar.
Figure 9: Average length of primary dendrite 
for each neurons within each treatment 
group (𝛍m).
Treatment 
Groups:
1. Control
2. Control + MB
3. DFO
4. DFOR
5. DFO + MB
6. DFOR + MB
DFO = Deferoxamine (Iron Chelator) DIV = Days In Vitro
Analyses
Dendrite complexity (branching and length) was determined through dendrite 
tracing and sholl analysis.
Statistics
Statistical signiﬁcance was determined using a one-way and two-way ANOVA 
tests. Asteriks represent a signiﬁcant difference between that treatment group 
and the control. The same letter above bars on the graphs represent no 
signiﬁcant difference between the groups.
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